Compare Amgen, Inc. (AMGN) vs UiPath Inc (PATH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs UiPath Inc — how do they compare? Amgen, Inc. trades at $364.5 (market cap $196.12B), while UiPath Inc trades at $11.78 (market cap $6.05B). The key difference: Amgen, Inc. is far larger — about 32.4× UiPath Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while UiPath Inc pays none. Which is the better fit depends on your goals.
| AMGN | PATH | |
|---|---|---|
Market Cap | $196.12B | $6.05B |
Sector | Health | Technology |
52-Week High | $388.16 | $19.29 |
52-Week Low | $271.18 | $9.38 |
Enterprise Value | $241.41B | $4.83B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
UiPath (PATH) trades at $11.68, down 1.02% on the day, with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while narrowing losses from -$74M to projected $327M profit. Recent product launches like Maestro Case expand enterprise automation capabilities. Analyst consensus price target sits at $13.33, representing 14% upside potential from current levels.
PATH presents a compelling growth story with strong revenue expansion and path to profitability, though elevated valuation multiples and competitive pressures warrant caution. The stock's current pullback offers entry opportunity for investors bullish on enterprise automation adoption, with key risks including execution on AI strategy and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
